The technology is superior at identifying cell types in human
blood, providing faster and more reliable assessments for clinical
decision making
SANTA CLARA, Calif.,
Sept. 15, 2020 /PRNewswire/ -- Based
on its recent analysis of the global hematology testing market,
Frost & Sullivan recognizes Beckman Coulter
Diagnostics with the 2020 Global New Product Innovation Award
for the DxH 690T. The company developed the tabletop hematology
analyzer for mid-volume laboratories, community hospitals and
physician offices, without compromising clinical effectiveness.
With 93% first-pass yield and 75% fewer quality control steps
compared to other commercially-available systems, the DxH 690T
provides laboratories a more streamlined workflow with increased
uptime and lower overhead costs.
"The DxH 690T leverages flagship products in the Beckman Coulter
Diagnostics' portfolio, specifically the enhanced Coulter
Principle, VCS technology and DataFusion, to provide precise
cellular assessments of RBCs, WBCs and platelets. The DxH 690T is
more effective and efficient than competing devices at detecting
the variety of cell types and morphologies, particularly with
abnormalities," said Norma Vela Industry Analyst, Frost &
Sullivan. "The DxH 690T reduces the need for manual interventions
and specimen re-dos, thus streamlining laboratory workflows and
increasing productivity."
The DxH 690T's automated capabilites are a significant benefit
because of worker shortages and financial pressures in healthcare.
Beckman Coulter designed the DxH 690T with medium-sized hospitals
and mid-volume laboratories in mind to increase walkaway times,
minimize touchpoints and maximize uptime.
Significantly, the DxH 690T also supports early detection of
sepsis for adult patients in the emergency department with the
Early Sepsis Indicator (ESId). The only FDA-cleared hematology
biomarker for sepsis, ESId measures monocyte distribution width
(MDW) to provide insight into the often deadly condition. Unlike
existing hematology analyzers, Beckman Coulter's DxH 690T includes
ESId that extracts information about sepsis' presence through
monocyte morphology. Beckman Coulter's technology uniquely
identifies changes in the volume of the monocyte population that
can aid in detecting patients with sepsis or at risk for
sepsis.
"While competitors typically eliminate some features and
capabilities for the mid-volume market, Beckman Coulter retains as
many high-volume analyzer capabilities and features as possible,"
noted John Scarpa Industry Analyst. "The instrument leverages the
company's experience in hematology innovation and complements its
broad hematology portfolio, including the DxH 520 for low-volume,
the DxH 900 for high-volume, and the DxH connected workcell
solutions for ultra-high-volume facilities."
Each year, Frost & Sullivan presents this award to the
company that has developed an innovative element in a product by
leveraging leading-edge technologies. The award recognizes the
value-added features/benefits of the product and the increased
return on investment (ROI) it gives customers, which, in turn,
raises customer acquisition and overall market penetration
potential.
"We are truly honored to receive this important industry
recognition," said Peter Soltani,
Ph.D., senior vice president and general manager of hematology at
Beckman Coulter. "The DxH 690T is a key part of our hematology
solutions portfolio and innovation strategy to deliver the power
and technology small-, medium- and large-volume laboratories need
to make more informed clinical decisions that help improve patient
outcomes."
Frost & Sullivan Best Practices Awards recognize companies
in a variety of regional and global markets for demonstrating
outstanding achievement and superior performance in areas such as
leadership, technological innovation, customer service, and
strategic product development. Industry analysts compare market
participants and measure performance through in-depth interviews,
analyses, and extensive secondary research to identify best
practices in the industry.
About Beckman Coulter Diagnostics
Beckman Coulter is
committed to advancing healthcare for every person by applying the
power of science, technology and the passion and creativity of our
teams to enhance the diagnostic laboratory's role in improving
healthcare outcomes. Our diagnostic systems are used in complex
biomedical testing, and are found in hospitals, reference
laboratories and physician office settings around the globe.
Beckman Coulter offers a unique combination of people, processes
and solutions designed to elevate the performance of clinical
laboratories and healthcare networks. We do this by accelerating
care with a menu that matters, bringing the benefit of automation
to all, delivering greater insights through clinical informatics
and unlocking hidden value through performance partnership. An
operating company of Danaher Corporation (NYSE: DHR) since 2011,
Beckman Coulter is headquartered in Brea,
Calif., and has more than 11,000 global associates working
diligently to make the world a healthier place. For more
information, visit www.BeckmanCoulter.com.
About Frost & Sullivan
For over five decades,
Frost & Sullivan has become world-renowned for its role in
helping investors, corporate leaders, and governments navigate
economic changes and identify disruptive technologies, Mega Trends,
new business models, and companies to action, resulting in a
continuous flow of growth opportunities to drive future success.
Contact us: Start the discussion.
Contact:
Kristen Moore
P: 210.247.3823
E: kristen.moore@frost.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/beckman-coulter-lauded-by-frost--sullivan-for-accelerating-sepsis-detection-with-the-dxh-690t-301131139.html
SOURCE Frost & Sullivan